v3.25.2
Schedule of operating results of company’s segment (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Research and development            
Total research and development $ 2,700,939   $ 1,881,093   $ 4,923,565 $ 3,688,078
Total general and administrative 1,949,035   1,325,087   3,432,444 2,466,319
Operating loss (4,649,974)   (3,206,180)   (8,356,009) (6,154,397)
Interest and other income (expense), net (138,761)   (3,497)   (235,417) (27,757)
Loss before income taxes (4,788,735)   (3,209,677)   (8,591,426) (6,182,154)
Income tax benefit (expense)    
Net loss and comprehensive loss (4,788,735) $ (3,802,691) (3,209,677) $ (2,972,477) (8,591,426) (6,182,154)
Clinical Operations [Member]            
Research and development            
Total research and development 763,860   65,966   1,871,334 1,143,156
Drug Manufacturing and Formulation [Member]            
Research and development            
Total research and development 1,110,084   1,462,519   1,490,437 1,803,718
Personnel [Member]            
Research and development            
Total research and development 409,220   343,762   970,554 649,714
Total general and administrative 459,336   404,586   1,030,866 817,863
Regulatory [Member]            
Research and development            
Total research and development 417,775   8,846   591,240 91,490
Legal and Professional Fees [Member]            
Research and development            
Total general and administrative 968,987   494,468   1,474,487 810,153
Occupancy [Member]            
Research and development            
Total general and administrative 88,359   73,846   149,986 174,533
Insurance [Member]            
Research and development            
Total general and administrative 174,449   241,524   370,045 483,048
Other [Member]            
Research and development            
Total general and administrative $ 257,904   $ 110,663   $ 407,060 $ 180,722